Goddard, C
Cagrilintides gastric effect is inferred with reasonable confidence from receptor pharmacology, animal data, and its gastrointestinal side-effect profile, but published monotherapy trials did not center on validated gastric-emptying measurements (scintigraphy or breath testing) tracked over time
\Safety Profile: Mild, transient side effects
Epub 2024/07/20
Given that the Phase I clinical trial in IPF demonstrated a reduction of senescent cells and SASP within eleven days after a single treatment of D+Q, and improvements in physiological outcomes after 10 weeks (105), we reasoned that a three-month period would provide important feasibility, compliance and efficacy data, as well as potentially reveal other cognitive and biomarker effects useful for designing a larger study
A favorable recommendation from the FDA's Pharmacy Compounding Advisory Committee (PCAC), scheduled for review in July 2026, followed by formal rulemaking, is required before legal compounding access is restored